CytoSite Bio Company Profile

Background

Overview

CytoSite Bio is a biotechnology company specializing in the development of innovative radiopharmaceuticals that leverage granzyme B, a key protein in the immune system's response to cancer cells. The company's mission is to enhance the precision and effectiveness of immunotherapy treatments by providing real-time insights into immune activity. Founded in 2016, CytoSite Bio is headquartered in Sudbury, Massachusetts.

Mission and Vision

CytoSite Bio aims to revolutionize immunotherapy by harnessing the power of granzyme B to transform cancer and autoimmune disease treatments. Their vision is to provide a dual-pronged approach to radiodiagnostics and radiotherapeutics, offering real-time assessments of immune responses and targeted therapies that reinvigorate the immune system to combat cancer cells.

Primary Area of Focus

The company's primary focus is on developing radiopharmaceutical agents that detect and quantify T cell and NK cell activation through granzyme B PET imaging. This approach enables clinicians to monitor immune responses in real-time, facilitating more accurate and timely decisions in immunotherapy treatments.

Industry Significance

CytoSite Bio's innovative use of granzyme B PET imaging positions it at the forefront of precision medicine, particularly in the field of immuno-oncology. By providing non-invasive, whole-body imaging of immune activity, the company offers a valuable tool for assessing the efficacy of immunotherapies, potentially improving patient outcomes and accelerating the development of new cancer treatments.

Key Strategic Focus

Core Objectives

• Advancement of Granzyme B PET Imaging: Develop and commercialize radiopharmaceutical agents that enable real-time monitoring of immune responses in cancer patients.

• Integration of Diagnostics and Therapeutics: Combine diagnostic imaging with targeted radiotherapeutic approaches to enhance the effectiveness of immunotherapy treatments.

Specific Areas of Specialization

• Granzyme B Targeting: Utilize granzyme B as a biomarker to assess immune-mediated tumor killing, providing insights into the tumor microenvironment and the effectiveness of immunotherapies.

• Radiopharmaceutical Development: Design and produce radiopharmaceutical agents for PET imaging and targeted radiotherapy, focusing on precision and safety.

Key Technologies Utilized

• Granzyme B PET Imaging: Employ positron emission tomography (PET) imaging agents that specifically bind to active granzyme B, allowing visualization of immune cell activity within tumors.

• Radiotherapeutic Agents: Develop radiopharmaceuticals that deliver targeted radiation to tumor sites, utilizing the granzyme B pathway to enhance immune-mediated tumor destruction.

Primary Markets or Conditions Targeted

• Cancer Immunotherapy: Provide tools for assessing and improving the efficacy of immunotherapies in various cancers, including melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer.

• Autoimmune Diseases: Explore applications of granzyme B PET imaging in monitoring immune activity in autoimmune conditions, potentially guiding treatment decisions.

Financials and Funding

Funding History

CytoSite Bio has raised a total of $7.87 million in funding, with the most recent round being a Series A - II, raising $3.05 million approximately six years ago.

Notable Investors

Specific details about individual investors are not publicly disclosed.

Intended Utilization of Capital

The funds have been allocated towards the development and clinical validation of granzyme B PET imaging agents, expansion of the company's radiopharmaceutical pipeline, and operational scaling to support ongoing and future clinical trials.

Pipeline Development

Key Pipeline Candidates

• CSB-321: A granzyme B-targeted PET imaging agent designed to visualize immune activity within tumors. Clinical trials have demonstrated its effectiveness in detecting immune responses in melanoma and NSCLC patients.

• CSB-421: An investigational radiotherapeutic agent that targets granzyme B to deliver localized radiation to tumor sites, aiming to enhance immune-mediated tumor destruction. Preclinical studies have shown promising results, including a 100% complete response rate in animal models.

Stages of Clinical Trials or Product Development

• CSB-321: Completed Phase I clinical trials, with ongoing Phase II studies to further assess its diagnostic capabilities across various cancer types.

• CSB-421: In preclinical development, with plans for IND submission and subsequent clinical trials pending regulatory approval.

Target Conditions

• CSB-321: Melanoma, NSCLC, and other solid tumors.

• CSB-421: Various cancers, including melanoma, NSCLC, and colorectal cancer.

Relevant Timelines for Anticipated Milestones

• CSB-321: Anticipated completion of Phase II trials and potential regulatory submissions within the next 2-3 years.

• CSB-421: Expected to enter clinical trials within the next 1-2 years, contingent upon successful preclinical outcomes and regulatory approvals.

Technological Platform and Innovation

Proprietary Technologies

• Granzyme B PET Imaging Agents: Developed to specifically target and visualize active granzyme B, providing real-time insights into immune responses within tumors.

• Radiotherapeutic Agents Targeting Granzyme B: Designed to deliver targeted radiation to tumor sites, utilizing the granzyme B pathway to enhance immune-mediated tumor destruction.

Significant Scientific Methods

• Granzyme B Targeting: Leveraging the role of granzyme B in immune-mediated tumor killing to develop diagnostic and therapeutic agents.

• PET Imaging Technology: Utilizing positron emission tomography to non-invasively visualize immune activity within the body.

• Radiopharmaceutical Development: